Literature DB >> 16461303

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.

Shmuel Yaccoby1, Michele J Wezeman, Maurizio Zangari, Ronald Walker, Michele Cottler-Fox, Danna Gaddy, Wen Ling, Rinku Saha, Bart Barlogie, Guido Tricot, Joshua Epstein.   

Abstract

BACKGROUND AND OBJECTIVES: Multiple myeloma (MM) growth in the bone marrow is associated with increased osteoclast activity and a reduced number of osteoblasts. Experimental studies suggest that bone disease drives the progression of MM. Whereas those studies focused on the critical role of myeloma-induced osteoclastogenesis in disease progression, little is known about the impact of osteoblasts and increased bone formation on MM. DESIGN AND METHODS: We investigated the effect of isolated osteoblasts and osteoclasts on survival and proliferation of primary MM plasma cells (PC) in co-cultures and triple-cultures, and tested the effect of mesenchymal stem cells (MSC) on bone mineral density and MM growth in myelomatous human bones of SCID-hu mice.
RESULTS: Whereas osteoclasts promoted survival and proliferation of MM PC, osteoblasts supported or inhibited MM PC, depending on the source of the MM cells. In triple-cultures osteoblasts attenuated the effect of osteoclasts on MM PC in 18 of 24 experiments. The anti-MM response to osteoblasts correlated with advanced clinical stage. Injection of MSC into myelomatous bones resulted in marked inhibition of tumor growth in three of nine experiments and stabilization of disease in two additional experiments. The anti-MM response of MSC was associated with increased human bone mineral density. Immunohistochemical analysis indicated that the MSC were well engrafted and, in responding mice, differentiated into osteogenic cells. INTERPRETATION AND
CONCLUSIONS: MM PC from the majority of patients are susceptible to growth inhibition by osteoblasts; however, growth of MM PC from certain patients is accelerated by osteoblasts. In vivo, increased bone formation is associated with reduced myeloma burden.

Entities:  

Mesh:

Year:  2006        PMID: 16461303      PMCID: PMC1592551     

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  40 in total

1.  Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation.

Authors:  S P Bruder; N S Ricalton; R E Boynton; T J Connolly; N Jaiswal; J Zaia; F P Barry
Journal:  J Bone Miner Res       Date:  1998-04       Impact factor: 6.741

2.  Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

Authors:  R Bataille; D Chappard; C Marcelli; P Dessauw; P Baldet; J Sany; C Alexandre
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

3.  Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.

Authors:  E M Horwitz; D J Prockop; L A Fitzpatrick; W W Koo; P L Gordon; M Neel; M Sussman; P Orchard; J C Marx; R E Pyeritz; M K Brenner
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

4.  Multilineage potential of adult human mesenchymal stem cells.

Authors:  M F Pittenger; A M Mackay; S C Beck; R K Jaiswal; R Douglas; J D Mosca; M A Moorman; D W Simonetti; S Craig; D R Marshak
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

5.  The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects.

Authors:  S P Bruder; K H Kraus; V M Goldberg; S Kadiyala
Journal:  J Bone Joint Surg Am       Date:  1998-07       Impact factor: 5.284

6.  Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice.

Authors:  R F Pereira; K W Halford; M D O'Hara; D B Leeper; B P Sokolov; M D Pollard; O Bagasra; D J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

7.  Connexin43 mediates direct intercellular communication in human osteoblastic cell networks.

Authors:  R Civitelli; E C Beyer; P M Warlow; A J Robertson; S T Geist; T H Steinberg
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption.

Authors:  T Taube; M N Beneton; E V McCloskey; S Rogers; M Greaves; J A Kanis
Journal:  Eur J Haematol       Date:  1992-10       Impact factor: 2.997

9.  Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.

Authors:  S Yaccoby; B Barlogie; J Epstein
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

10.  Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells.

Authors:  H Hata; H Xiao; M T Petrucci; J Woodliff; R Chang; J Epstein
Journal:  Blood       Date:  1993-06-15       Impact factor: 22.113

View more
  60 in total

Review 1.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 2.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

3.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

Review 4.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 5.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

6.  Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.

Authors:  Xin Li; Angela Pennisi; Fenghuang Zhan; Jeffrey R Sawyer; John D Shaughnessy; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

7.  Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.

Authors:  Shuji Ozaki; Osamu Tanaka; Shiro Fujii; Yuri Shigekiyo; Hirokazu Miki; Masahito Choraku; Kumiko Kagawa; Jin Asano; Kyoko Takeuchi; Ken-ichi Kitazoe; Toshihiro Hashimoto; Masahiro Abe; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

8.  Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Authors:  Rakesh Bam; Wen Ling; Sharmin Khan; Angela Pennisi; Sathisha Upparahalli Venkateshaiah; Xin Li; Frits van Rhee; Saad Usmani; Bart Barlogie; John Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2013-03-28       Impact factor: 10.047

9.  In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

Authors:  Enrique M Ocio; David Vilanova; Peter Atadja; Patricia Maiso; Edvan Crusoe; Diego Fernández-Lázaro; Mercedes Garayoa; Laura San-Segundo; Teresa Hernández-Iglesias; Enrique de Alava; Wenlin Shao; Yung-Mae Yao; Atanasio Pandiella; Jesús F San-Miguel
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

Review 10.  Concise review: adult multipotent stromal cells and cancer: risk or benefit?

Authors:  Gwendal Lazennec; Christian Jorgensen
Journal:  Stem Cells       Date:  2008-04-03       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.